The combined use of radiation therapy and lonidamine in the treatment of brain metastases Journal Article


Authors: DeAngelis, L. M.; Currie, V. E.; Kim, J. H.; Krol, G.; O'Hehir, M. A.; Farag, F. M.; Young, C. W.; Posner, J. B.
Article Title: The combined use of radiation therapy and lonidamine in the treatment of brain metastases
Abstract: Lonidamine is an indazole carboxylic acid that has been shown to be synergistic with radiotherapy (RT) in tissue culture and animal models. Clinical experience has shown that lonidamine is well-tolerated, and appears to potentiate the activity of conventional chemotherapy in the treatment of brain metastases. A prospective randomized trial was undertaken to evaluate the use of lonidamine in combination with RT in the treatment of brain metastases. All patients received 3000 cGy of whole brain radiotherapy (WBRT). Fifty eight patients were enrolled; 31 received lonidamine plus WBRT and 27 received WBRT alone. There was no significant difference in response rate or survival between the treatment groups. Lonidamine blood levels were measured in 30 of the 31 patients who received the drug, and were therapeutic (≥ 15 μg/ml) in 50%. Survival and response rate were unaffected by the presence or absence of a therapeutic lonidamine level. The most common side-effects of lonidamine were myalgia, testicular pain, anorexia, and ototoxicity; however, only 2 patients had to discontinue the drug because of intolerable myalgias. No serious organ toxicity or myelosuppression was observed. © 1989 Kluwer Academic Publishers.
Keywords: adult; controlled study; aged; major clinical study; antineoplastic agents; combined modality therapy; brain neoplasms; prospective studies; anorexia; myalgia; radiotherapy; randomized controlled trials; pyrazoles; brain metastasis; radiosensitizing agent; oral drug administration; brain metastases; lonidamine; ototoxicity; middle age; indazoles; human; male; female; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; radiosensitizer; orchialgia
Journal Title: Journal of Neuro-Oncology
Volume: 7
Issue: 3
ISSN: 0167-594X
Publisher: Springer  
Date Published: 1989-09-01
Start Page: 241
End Page: 247
Language: English
DOI: 10.1007/bf00172917
PUBMED: 2677257
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 14 April 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jerome B Posner
    211 Posner
  2. George Krol
    86 Krol
  3. Violante Currie
    51 Currie
  4. Charles W Young
    82 Young
  5. Maureen A O'Hehir
    3 Ohehir
  6. Jae Ho Kim
    25 Kim